109 reports of this reaction
1.5% of all HYDROXYZINE PAMOATE reports
#20 most reported adverse reaction
RESPIRATORY ARREST is the #20 most commonly reported adverse reaction for HYDROXYZINE PAMOATE, manufactured by Amneal Pharmaceuticals of New York LLC. There are 109 FDA adverse event reports linking HYDROXYZINE PAMOATE to RESPIRATORY ARREST. This represents approximately 1.5% of all 7,494 adverse event reports for this drug.
Patients taking HYDROXYZINE PAMOATE who experience respiratory arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY ARREST is a less commonly reported adverse event for HYDROXYZINE PAMOATE, but still significant enough to appear in the safety profile.
In addition to respiratory arrest, the following adverse reactions have been reported for HYDROXYZINE PAMOATE:
The following drugs have also been linked to respiratory arrest in FDA adverse event reports:
RESPIRATORY ARREST has been reported as an adverse event in 109 FDA reports for HYDROXYZINE PAMOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY ARREST accounts for approximately 1.5% of all adverse event reports for HYDROXYZINE PAMOATE, making it a notable side effect.
If you experience respiratory arrest while taking HYDROXYZINE PAMOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.